Industry Bulletins | March 10, 2021
Pear Therapeutics Closes $100 Million Series D Funding Round
Pear Therapeutics announced the second closing of its Series D financing round. The second closing included a leading national integrated delivery network (IDN) as a new strategic investor. The national IDN is investing $20 million, bringing the total Series D investment to $100 million. Pear Therapeutics develops and markets prescription digital therapeutics (PDTs), a new therapeutic class that uses software to treat disease through a consumer's mobile device when and where they need it most.
The company is using its Series D financing to accelerate reimbursement coverage for its products authorized by the U.S. Food and Drug Administration . . .